Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Angiotensin-(1-7) vs Apelin
An educational, source-based comparison of Angiotensin-(1-7) and Apelin — how each peptide works, what it's researched for, and what to know before going deeper.
Counter-regulatory peptide of the renin-angiotensin system.
A heptapeptide of the renin-angiotensin system that acts on Mas receptors. Research demonstrates counter-regulatory effects to angiotensin II, promoting vasodilation, anti-inflammatory signaling, and anti-fibrotic effects in cardiovascular and renal tissues.
- Pulmonary hypertension and fibrosis
- Heart failure with preserved ejection fraction
- Acute lung injury and ARDS
- Diabetic nephropathy
- • Investigational; not FDA-approved.
- • Interaction with ACE inhibitors and ARBs requires careful study design.
An endogenous peptide ligand for the APJ receptor, widely expressed in cardiovascular and metabolic tissues. Research indicates roles in cardiac contractility, angiogenesis, blood pressure regulation, and insulin sensitivity.
- Heart failure and cardiac contractility
- Pulmonary arterial hypertension
- Insulin sensitivity and glucose uptake
- Angiogenesis and vascular repair
- • Primarily preclinical and early clinical research.
- • Not FDA-approved for any indication.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Two cited studies; independent replication needed.
Two cited studies; independent replication needed.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Angiotensin-(1-7) | Angiotensin-(1-7) as a therapeutic in lung disease | American Journal of Respiratory and Critical Care Medicine | 2020 | Demonstrated protective effects in acute lung injury and pulmonary fibrosis models. |
| Angiotensin-(1-7) | Mas receptor activation in cardiovascular protection | Circulation Research | 2018 | Reviewed anti-inflammatory and anti-fibrotic mechanisms in cardiac tissue. |
| Apelin | Apelin in heart failure: a new therapeutic target | Journal of the American College of Cardiology | 2019 | Reviewed cardioprotective mechanisms and therapeutic potential in heart failure. |
| Apelin | Apelin improves insulin sensitivity in obese models | Diabetes | 2014 | Enhanced glucose uptake and insulin signaling in adipose and muscle tissue. |
Side-effect & safety grid
- Investigational; not FDA-approved.
- Interaction with ACE inhibitors and ARBs requires careful study design.
- Primarily preclinical and early clinical research.
- Not FDA-approved for any indication.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Angiotensin-(1-7) vs Apelin — Key differences
- Class: Angiotensin-(1-7) is classified as Cardiovascular · Anti-inflammatory, while Apelin is Cardiovascular · Metabolic.
- Primary research focus: Angiotensin-(1-7) — pulmonary hypertension and fibrosis; Apelin — heart failure and cardiac contractility.
- Tag: Cardiovascular · Anti-inflammatory vs Cardiovascular · Metabolic.